Multifaceted regulation of cell cycle progression by estrogen: Regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function

Molecular and Cellular Biology

Volumn 21, Issue 3, 2001, Pages 794-810

  Foster, J S ^a   Henley, D C ^a   Bukovsky, A ^a   Seth, P ^a   Wimalasena, J ^a  

^a UNIVERSITY OF TENNESSEE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CYCLIN A; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; MESSENGER RNA; PROTEIN CDC25A; PROTEIN P16; PROTEIN P21; PROTEIN P27; PROTEIN TYROSINE PHOSPHATASE; RECOMBINANT ENZYME; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

ADENOVIRUS; ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; COMPLEX FORMATION; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; ENZYME ACTIVATION; ENZYME INHIBITION; ESTROGEN ACTIVITY; FEMALE; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HORMONAL REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ADENOVIRIDAE; BASE SEQUENCE; BREAST NEOPLASMS; CARRIER PROTEINS; CDC2-CDC28 KINASES; CDC25 PHOSPHATASE; CELL CYCLE; CELL CYCLE PROTEINS; CYCLIN D1; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; CYCLINS; ESTROGENS; FEMALE; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; MODELS, BIOLOGICAL; NEOPLASMS, HORMONE-DEPENDENT; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RECEPTORS, ESTROGEN; RETINOBLASTOMA PROTEIN; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

ADENOVIRIDAE; MINK CELL FOCUS-FORMING VIRUS;

EID: 0035139077     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.21.3.794-810.2001     Document Type: Article

References (104)

1. 17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells
2. Estrogen induces early and timed activation of cyclin-dependent kinases 4, 5, and 6 and increases cyclin messenger ribonucleic acid expression in rat uterus
3. 1/S transition and leads to premature activation of cyclin E- and cyclin A-dependent kinases
4. Increased p16 expression with first senescence arrest in human mammary epithelial cells and extended growth capacity with p16 inactivation
5. Role of the Cdc25A phosphatase in human breast cancer
6. Non-transcriptional action of oestradiol and progestin triggers DNA synthesis
7. mdm2 and bax, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway
8. Serum-induced expression of the cdc25A gene by relief of E2F-mediated repression
9. Effects of adenovirus-mediated p16INK4A expression on cell cycle arrest are determined by endogenous p16 and Rb status in human cancer cells
10. A recombinant adenovirus expressing p27Kip1 induces cell cycle arrest and loss of cyclin-Cdk activity in human breast cancer cells
11. 1/S-regulatory genes
12. Stimulation of c-myc oncogene expression associated with estrogen-induced proliferation of human breast cancer cells
13. Transcriptional regulation of c-myc oncogene expression by estrogen in hormone-responsive human breast cancer cells
14. Mechanism of estrogen activation of c-myc oncogene expression
15. Mice lacking cyclin D1 are small and show defects in eye and mammary gland development
16. Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells
17. Inactivation of p16 in human mammary epithelial cells by CpG island methylation
18. Specific activation of cdc25 tyrosine phosphatases by B-type cyclins: Evidence for multiple roles of mitotic cyclins
19. Cdc25 cell-cycle phosphatase as a target of c-myc
20. Raf1 interaction with Cdc25 phosphatase ties mitogenic signal transduction to cell cycle activation
21. CDC25 phosphatases as potential human oncogenes
22. Cdc25 is a specific tyrosine phosphatase that directly activates p34cdc2
23. Regulation of cyclin E transcription by E2Fs and retinoblastoma protein
24. Estrogen-induced cyclin D1 and D3 gene expressions during mouse uterine cell proliferation in vivo: Differential induction mechanism of cyclin D1 and D3
25. Cyclin E, a redundant cyclin in breast cancer
26. Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15
27. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases
28. Activation of the phosphatase activity of human cdc25A by a cdk2-cyclin E dependent phosphorylation at the G1/S transition
29. Cyclin D1 and estrogen receptor messenger RNA levels are positively correlated in primary breast cancer
30. Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-beta in cells lacking the CDK inhibitor p15
31. E2F and histone deacetylase mediate transforming growth factor β repression of cdc25A during keratinocyte cell cycle arrest
32. Control of mammary gland development
33. INK4a-mediated growth suppression
34. Cdc25A is a novel phosphatase functioning early in the cell cycle
35. Induction of p27Kip1 degradation and anchorage independence by Ras through the MAP kinase signaling pathway
36. The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer
37. Redundant cyclin overexpression and gene amplification in breast cancer cells
38. The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2
39. Cyclin A is a functional target of retinoblastoma tumor suppressor protein-mediated cell cycle arrest
40. Negative regulation of G1 in mammalian cells: Inhibition of cyclin E-dependent kinase by TGF-beta
41. Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F
42. Mode of estrogen action on cell proliferation in CAMA-1 cells. II. Sensitivity of G1 phase population
43. Ubiquitous expression and cell cycle regulation of the protein kinase PIM-1
44. Oestrogen-responsive human breast cancer in long term tissue culture
45. 1 checkpoint
46. Cyclin E-induced S phase without activation of the pRb/E2F pathway
47. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16
48. D-type cyclin-dependent kinase activity in mammalian cells
49. INK4a inhibits both CDK4- and CDK2-associated kinase activity by reassortment of cyclin-CDK-inhibitor complexes
50. P/CAF associates with cyclin D1 and potentiates its activation of the estrogen receptor
51. Growth suppression by p16ink4 requires functional retinoblastoma protein
52. Chemical inhibitors of cyclin-dependent kinases
53. A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer
54. INK4a
55. Physical and functional interactions between Pim-1 kinase and Cdc25A phosphatase. Implications for the Pim-1-mediated activation of the c-Myc signaling pathway
56. Cdk2-dependent phosphorylation of p27 facilitates its Myc-induced release from cyclin E/cdk2 complexes
57. Inducible expression of cyclin D1 in T-47D human breast cancer cells is sufficient for Cdk2 activation and pRB hyperphosphorylation
58. Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4
59. Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status
60. Deregulation of cyclin E and D1 in breast cancer is associated with inactivation of the retinoblastoma protein
61. G1-S transition defects occur in most breast cancers and predict outcome
62. 1-to-S phase transition
63. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27
64. Lack of cyclin D-Cdk complexes in Rb-negative cells correlates with high levels of p16INK4/MTS1 tumour suppressor gene product
65. Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution
66. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest
67. A new cellular model of response to estrogens: A bioluminescent test to characterize (anti) estrogen molecules
68. Redistribution of the CDK inhibitor p27 between different cyclin-CDK complexes in the mouse fibroblast cell cycle and in cells arrested with lovastatin or ultraviolet irradiation
69. c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry
70. Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2
71. Estrogen activates raf-1 kinase and induces expression of Egr-1 in MCF-7 breast cancer cells
72. Rescue of defective mitogenic signaling by D-type cyclins
73. CIP1 and Cdc25A: Competition between an inhibitor and an activator of cyclin-dependent kinases
74. Progesterone, in addition to estrogen, induces cyclin D1 expression in the murine mammary epithelial cell, in vivo
75. 1/S-promoting mechanism parallel to the pRb/E2F pathway
76. Cell cycle regulation of the cyclin Agene promoter is mediated by a variant E2F site
77. Ras enhances Myc protein stability
78. Cdc25M2 activation of cyclin-dependent kinases by dephosphorylation of threonine-14 and tyrosine-15
79. A rate limiting function of cdc25A for S phase entry inversely correlates with tyrosine dephosphorylation of Cdk2
80. Cyclin E-CDK2 is a regulator of p27Kip1
81. D-type cyclins
82. Cancer cell cycles
83. Inhibitors of mammalian G1 cyclin-dependent kinases
84. CDK inhibitors: Positive and negative regulators of G1-phase progression
85. Cyclin D1 provides a link between development and oncogenesis in the retina and breast
86. Estrogen responsive proliferation of clonal human breast carcinoma cells in athymic mice
87. Cell proliferation kinetics of MCF-7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells
88. Lack of relationship between CDK activity and G1 cyclin expression in breast cancer cells
89. kip1 downregulation, passage through the restriction point, and entry into S phase in growth factor-stimulated NIH 3T3 fibroblasts
90. Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1
91. Progesterone inhibits estrogen-induced cyclin D1 and cdk4 nuclear translocation, cyclin E- and cyclin A-cdk2 kinase activation, and cell proliferation in uterine epithelial cells in mice
92. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21
93. Distinct roles for cyclin-dependent kinases in cell cycle control
94. CDC25A phosphatase is a target of E2F and is required for efficient E2F-induced S phase
95. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice
96. Transcriptional activation of E2F1 gone expression by 17beta-estradiol in MCF-7 cells is regulated by NF-Y-Sp1/estrogen receptor interactions
97. Ary1 hydrocarbon receptor-mediated antiestrogenicity in MCF-7 cells: Modulation of hormone-induced cell cycle enzymes
98. Antiestrogen inhibition of cell cycle progression in breast cancer cells is associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation
99. The retinoblastoma protein and cell cycle control
100. Tyrosine phosphorylation of the proto-oncoprotein Raf-1 is regulated by Raf-1 itself and the phosphatase Cdc25A
101. Down-regulation of the cyclin A promoter by transforming growth factor-beta1 is associated with a reduction in phosphorylated activating transcription factor-1 and cyclic AMP-responsive element-binding protein
102. Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1
103. Cyclin D1 triggers autonomous growth of breast cancer cells by governing cell cycle exit
104. CDK-independent activation of estrogen receptor by cyclin D1